The estimated Net Worth of Kavita Patel is at least 4.85 百万$ dollars as of 14 November 2023. Kavita Patel owns over 203,125 units of Sigilon Therapeutics stock worth over 4,846,622$ and over the last 9 years Kavita sold SGTX stock worth over 0$.
Kavita has made over 3 trades of the Sigilon Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently Kavita exercised 203,125 units of SGTX stock worth 4,564,219$ on 14 November 2023.
The largest trade Kavita's ever made was exercising 203,125 units of Sigilon Therapeutics stock on 14 November 2023 worth over 4,564,219$. On average, Kavita trades about 15,407 units every 50 days since 2016. As of 14 November 2023 Kavita still owns at least 215,693 units of Sigilon Therapeutics stock.
You can see the complete history of Kavita Patel stock trades at the bottom of the page.
Kavita's mailing address filed with the SEC is C/O SELECTQUOTE, INC., 6800 WEST 115TH STREET, STE 2511, OVERLAND PARK, KS, 66211.
Over the last 4 years, insiders at Sigilon Therapeutics have traded over 2,000,000$ worth of Sigilon Therapeutics stock and bought 2,018,493 units worth 31,039,916$ . The most active insiders traders include Lilly & Co Eli、Lilly & Co Shenandoah Acqui...、John Cox. On average, Sigilon Therapeutics executives and independent directors trade stock every 139 days with the average trade being worth of 7,174,671$. The most recent stock trade was executed by Lilly & Co Shenandoah Acqui... on 11 August 2023, trading 1,718,493 units of SGTX stock currently worth 25,639,916$.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Sigilon Therapeutics executives and other stock owners filed with the SEC include: